Search Results for:
-
Financings Roundup
Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said it commenced a public offering of 10.5 million shares of its Class A common stock...NPS Pharmaceuticals Inc., of Bedminster, N.J., is commencing a public offering of 6 million shares of common stockBioWorld Today | Wednesday, May 22, 2013 -
Biotech Collaborations Between Pharmaceutical & Miscellaneous Companies: April 1 - May 16, 2013
they will share revenues and certain costs on a 60/40 basis, with Merck taking on the larger share 4/30/13 NovaDel Pharma Inc. (Bridgewater, N.J.) Suda Ltd. (Australia) $0.4 Agreement to sell its NovaMist technology and certain additional assets to Suda NovaDel will receive $400,000 in cash, 50M shares of Suda common stock and 10M options to purchase Suda common shares at 5 cents per share 4/9/13 Perosphere Inc. (Mount Kisco, N.Y.) Daiichi Sankyo CoBioWorld Insight | Monday, May 20, 2013 -
Week in Review
priced a $100 million public offering of 8 million shares of common stock...reported that a 20-to-1 reverse stock split of its common stock is effectiveBioWorld Insight | Monday, May 20, 2013 -
As Markets Fancy Biotech, PTC Therapeutics Joins IPO Queue
The company said it had 1.1 million shares of common stock outstanding as of May 15 and 14.2 million additional shares that would be issued upon the automatic conversion of outstanding shares of its preferred stock at the offering's close...The 2015 notes are convertible on or before June 14 into shares of the company's common stock at a price of about $48.83 per share (20.4794 shares per $1,000 principal amountBy Marie Powers | BioWorld Today | Monday, May 20, 2013 -
Other News To Note
The court found that Emmaus had properly canceled all shares of its common stock held by AFH and that AFH and Heshmatpour must return to Emmaus all stock certificates representing the sharesBioWorld Today | Friday, May 17, 2013 -
Pharma: Other News To Note
The company plans to use proceeds to repurchase common stock and for general corporate purposes, including the repayment of outstanding commercial paper borrowings and upcoming debt maturitiesBioWorld Today | Friday, May 17, 2013 -
Other News To Note
Common stock in Fibrocell Science Inc., of Exton, Pa., has been approved for listing on the NYSE Market, to commence trading on May 17, under the ticker symbol FCSCBioWorld Today | Thursday, May 16, 2013 -
Tokai Adds $35.5M in Series E, Preps for Phase III CRPC Trials
Acadia Pharmaceuticals Inc., of San Diego, priced a $100 million public offering of 8 million shares of common stock at $12.50 apiece, a 3.5 percent discount to Tuesday's closing price...Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J, said it is offering to sell shares of its common stock in a public offeringBy Jennifer Boggs | BioWorld Today | Thursday, May 16, 2013 -
Financings Roundup
Omeros Corp., of Seattle, said it closed the registered direct offering of 3.9 million shares of common stock priced at $4.14 per share, raising net proceeds of about $16.1 millionBioWorld Today | Wednesday, May 15, 2013 -
Beyond Kalbitor: Dyax Adds $30M for HAE Prophylactic
Under the terms of its financing deal, Dyax priced a total of 8.9 million shares of common stock and 41,418 shares of Series 1 convertible preferred stock...MediciNova Inc., of San Diego, entered a securities purchase agreement, selling about 1.2 million shares of common stock priced at $3.15 apieceBy Jennifer Boggs | BioWorld Today | Tuesday, May 14, 2013 -
Other News To Note
Aastrom Biosciences Inc., of Ann Arbor, Mich., reported in an 8-K filing with the SEC that it was notified by Nasdaq that the bid price for its common stock closed below the minimum $1 per share requirement for 30 consecutive business daysBioWorld Today | Tuesday, May 14, 2013 -
Other News To Note
The split is intended to increase the per-share trading price of the common stock to satisfy the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market...Trading of the company's common stock on the Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the markets on May 13, under new CUSIP number 69207P308BioWorld Today | Monday, May 13, 2013 -
Financings Roundup
Discovery Laboratories Inc., of Warrington, Pa., said it priced a $14.25 million public offering of 9.5 million shares of common stock at $1.50, an 8.5 percent discount to Thursday's closing priceBioWorld Today | Monday, May 13, 2013 -
Isis Peers Beyond Kynamro, Seeks $171M for Pipeline
The Carlsbad, Calif.-based company priced an underwritten public offering of 9 million shares of its common stock at $19 per share, seeking to raise $171 million from the offering, which is expected to close on or about May 14...In its filing, Isis said it would have 111.7 million shares of common stock outstanding when the offering closesBy Marie Powers | BioWorld Today | Friday, May 10, 2013 -
Receptos Prices Solid IPO, Raises $72.8M for Pipeline
Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million...Senesco Technologies Inc., of Bridgewater, N.J., said it entered a securities purchase agreement with certain institutional investors to raise $1.255 million in gross proceeds through the sale of about 41 .8 million shares of common stock priced at 3 cents apieceBy Catherine Shaffer | BioWorld Today | Friday, May 10, 2013 -
Earnings Roundup
The increase is primarily due to proceeds of approximately $352 million received from a public offering of 4.4 million shares of common stock, completed in JanuaryBioWorld Today | Thursday, May 9, 2013 -
Lumena Large: $23M Series A Funds Phase II Cholestatic Bid
Under the terms, Zalicus has the right to sell up to $25 million in shares of its common stock to Lincoln Park subject to certain limitations and conditions set forth in the purchase agreement...Zalicus will control the timing and amount of any common stock sales to Lincoln Park.By Randy Osborne | BioWorld Today | Thursday, May 9, 2013 -
David Blech Charged with Securities Fraud Charge, Arraigned
A spokesman for GeneMedicine told BioWorld Today Blech currently owns 1 million shares of that company's common stock, but has no active involvement in its operationBio Perspectives | Wednesday, May 8, 2013 -
Week in Review
plans to purchase up to $15 billion of its common stockBioWorld Insight | Monday, May 6, 2013 -
Other Financings Of Public Biotechnology Companies: April 2013
to sell shares of common stock 4/19/13 Navidea Biopharma-ceuticals Inc. (Dublin, Ohio) At-the-market common stock offering 2.1S $5.1 Navidea raised $5.1M in an offering of 2.1M shares at $2.43 per shareBioWorld Insight | Monday, May 6, 2013
Category
Current Filters
- xcommon stock
Related Keywords
Categories
- x BioWorld Today (4981)
- x BioWorld Insight (500)
- x BioWorld International (106)
- x State of the Industry Report (72)
- x BioWorld Snapshots (50)
- x Executive Compensation Report (36)
- x Bio Perspectives (29)
- x BioWorld Genomics Review (15)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.